Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study

Aims: Whether pioglitazone (PIO), a peroxisome proliferator-activated receptor-gamma agonist, increases the risk of developing bladder cancer has been debated for several years. The aim of this study was to investigate the in vitro effects of PIO on normal urothelial transitional epithelium (NUTE) c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shao-ling, Wang, Ji-jiao, Chen, Ming, Xu, Lu, Li, Nan, Luo, Yi-li, Bu, Le, Zhang, Man-na, Li, Hong, Su, Ben-li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820852/
https://www.ncbi.nlm.nih.gov/pubmed/29483814
http://dx.doi.org/10.7150/ijms.22408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820852/
https://www.ncbi.nlm.nih.gov/pubmed/29483814
http://dx.doi.org/10.7150/ijms.22408

Ejemplares similares